A review revealed in JAMA Network Open up emphasizes the discrepancy amongst what it expenditures to produce copyright plus the retail price ranges patients encounter. Despite the small production expenses, Novo Nordisk has not publicly disclosed specific figures for copyright or its other product or service, Wegovy.In October 2024, Novo Nordisk pu